Showing 1 - 8 results of 8 for search 'José M Gatell', query time: 0.03s Refine Results
  1. 1
    Increased alpha-defensins 1-3 production by dendritic cells in HIV-infected individuals is associated with slower disease progression.

    Increased alpha-defensins 1-3 production by dendritic cells in HIV-infected individuals is associated with slower disease progression. by Marta Rodríguez-García, Núria Climent, Harold Oliva, Víctor Casanova, Rafael Franco, Agathe Leon, José M Gatell, Felipe García, Teresa Gallart

    Published 2010-02-01
    Get full text
    Article
  2. 2
    Prevalence, clinical characteristics and outcome of severe primary HIV-1 infection: A prospective cohort study

    Prevalence, clinical characteristics and outcome of severe primary HIV-1 infection: A prospective cohort study by David Nicolás, Antoni Suárez, Juan Ambrosioni, Christian Manzardo, Carmen Ligero, Josep Costa, Emma Fernández, M. Ángeles Marcos, Montserrat Plana, María Mar Mosquera, Sonsoles Sánchez-Palomino, Jose M. Gatell, José M. Miró

    Published 2019-11-01
    Get full text
    Article
  3. 3
    Adenosine deaminase enhances the immunogenicity of human dendritic cells from healthy and HIV-infected individuals.

    Adenosine deaminase enhances the immunogenicity of human dendritic cells from healthy and HIV-infected individuals. by Víctor Casanova, Isaac Naval-Macabuhay, Marta Massanella, Marta Rodríguez-García, Julià Blanco, José M Gatell, Felipe García, Teresa Gallart, Carme Lluis, Josefa Mallol, Rafael Franco, Núria Climent, Peter J McCormick

    Published 2012-01-01
    Get full text
    Article
  4. 4
    Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant.

    Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant. by Carolina Beltran-Pavez, Carolina B Ferreira, Alberto Merino-Mansilla, Amanda Fabra-Garcia, Maria Casadella, Marc Noguera-Julian, Roger Paredes, Alex Olvera, Isabel Haro, Christian Brander, Felipe Garcia, Jose M Gatell, Eloisa Yuste, Victor Sanchez-Merino

    Published 2018-01-01
    Get full text
    Article
  5. 5
    Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals.

    Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals. by Ai Kawana-Tachikawa, Josep M Llibre, Isabel Bravo, Roser Escrig, Beatriz Mothe, Jordi Puig, Maria C Puertas, Javier Martinez-Picado, Julia Blanco, Christian Manzardo, Jose M Miro, Aikichi Iwamoto, Anton L Pozniak, Jose M Gatell, Bonaventura Clotet, Christian Brander, MARAVIBOOST Investigators

    Published 2014-01-01
    Get full text
    Article
  6. 6
    Epidemiology and prognosis of coagulase-negative staphylococcal endocarditis: impact of vancomycin minimum inhibitory concentration.

    Epidemiology and prognosis of coagulase-negative staphylococcal endocarditis: impact of vancomycin minimum inhibitory concentration. by Cristina García de la Mària, Carlos Cervera, Juan M Pericàs, Ximena Castañeda, Yolanda Armero, Dolors Soy, Manel Almela, Salvador Ninot, Carlos Falces, Carlos A Mestres, Jose M Gatell, Asuncion Moreno, Francesc Marco, José M Miró, Hospital Clinic Endocarditis Study Group

    Published 2015-01-01
    Get full text
    Article
  7. 7
    Correction: Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.

    Correction: Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization. by Alberto C Guardo, Carmen Elena Gómez, Vicens Díaz-Brito, Judit Pich, Joan Albert Arnaiz, Beatriz Perdiguero, Juan García-Arriaza, Nuria González, Carlos O S Sorzano, Laura Jiménez, José Luis Jiménez, María Ángeles Muñoz-Fernández, José M Gatell, José Alcamí, Mariano Esteban, Juan Carlos López Bernaldo de Quirós, Felipe García, Montserrat Plana, RISVAC02boost study

    Published 2018-01-01
    Get full text
    Article
  8. 8
    Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.

    Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization. by Alberto C Guardo, Carmen Elena Gómez, Vicens Díaz-Brito, Judit Pich, Joan Albert Arnaiz, Beatriz Perdiguero, Juan García-Arriaza, Nuria González, Carlos O S Sorzano, Laura Jiménez, José Luis Jiménez, María Ángeles Muñoz-Fernández, José M Gatell, José Alcamí, Mariano Esteban, Juan Carlos López Bernaldo de Quirós, Felipe García, Montserrat Plana, RISVAC02boost study

    Published 2017-01-01
    Get full text
    Article

Search Tools: